Shanghai Pharmaceuticals: Placing Coverage Under Review
We are placing coverage of narrow-moat-rated Shanghai Pharmaceuticals 02607 under review pending the transfer of coverage to a new analyst. We expect to revisit our coverage of this company over the next three months. Our most recent fair value estimate was HKD 20.30.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.